(RTTNews) – Ascletis Pharma Inc. (ASCLF.PK) introduced that it has submitted internet marketing authorization application for ritonavir 100 mg film-coated pill in the Hong Kong Specific Administrative Location of the People’s Republic of China.
Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, mentioned, “In addition to filing advertising and marketing authorization applications for ritonavir in numerous nations around the world/regions, we are accelerating the improvement of ASC10 and ASC11, two novel oral drug candidates in opposition to COVID-19”.
Prognosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Model 9) produced on March 15, 2022 by the Countrywide Wellbeing Fee of the People’s Republic of China includes PF-07321332/ritonavir (Paxlovid) as an antiviral remedy, the organization mentioned.
Ascletis has submitted promoting authorization apps for ritonavir (100 mg movie-coated pill) in 12 European countries (Germany, France, Eire, the United Kingdom, Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) through its agent in Europe.
The sights and views expressed herein are the sights and opinions of the creator and do not essentially reflect individuals of Nasdaq, Inc.